AI-generated summary
The authors followed up six Parkinson's disease participants who had continued home-based photobiomodulation therapy for five years, after excluding one with a preliminary multisystem atrophy diagnosis. They report significant improvements in walk speed, stride length, timed up-and-go and dynamic balance, and cognition compared with baseline, while MDS-UPDRS-III was unchanged. The authors describe the findings as a signal rather than proof of benefit.
- Participants
- 8
- Who or what was studied
- Eight individuals with Parkinson's disease from an initial cohort of 12, of whom six were analyzed as a group after exclusions
- Limits stated in the abstract
- The sample was very small, the follow-up was uncontrolled, one participant was excluded, one measure of static balance declined, and the authors describe the results only as a signal.
Written by an AI model from this paper’s abstract only and checked automatically against it, but it can still be wrong. It is not medical advice. Read the full paper. See the editorial policy.
Abstract
The full abstract is not shown here because it is protected by the publisher’s copyright. Read it on bmcneurol.biomedcentral.com.
Record from PubMed, a service of the National Library of Medicine.
How to read a single study: what to check before relying on this kind of research.
Terms in this paper: Photobiomodulation, Photobiomodulation therapy, Trial registration. Each links to its definition in the glossary.
A summary of published research, not medical advice. One study rarely settles a question. See the disclaimer and how to read research.